heliox
Phase 3Small molecule
heliox is one of 101 small molecule programs targeting Bronchiolitis. It is currently in Phase 3.
3
Indications
6
Total Trials
1
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
149 competitors in Obstructive Sleep Apnea
#DrugCompanyPhaseTrials
1Foundayo
Eli LillyPhase 3
Mounjaro
Eli LillyPhase 3
Farxiga
AstraZenecaPhase 3
Asmanex
NovartisPhase 3
MS Contin
Merck & Co.Phase 3
Lunesta
Akero TherapeuticsPhase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
Imovane
TTaisho Pharmaceutical Co., Ltd.
Phase 3
Advil
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bronchiolitis2 trials
Respiratory Distress Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for heliox. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNorthwell Health